Abivax (ABVX) to Release Quarterly Earnings on Monday

Abivax (NASDAQ:ABVX) is projected to issue its Q1 2026 resultson Monday, May 25th. Analysts expect the company to announce earnings of ($0.9359) per share and revenue of $0.4010 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Monday, May 25, 2026 at 3:00 AM ET.

Abivax (NASDAQ:ABVX) last released its earnings results on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The firm had revenue of $0.52 million for the quarter. On average, analysts expect Abivax to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Abivax Price Performance

Abivax stock opened at $114.53 on Monday. Abivax has a twelve month low of $5.59 and a twelve month high of $148.83. The firm has a 50 day moving average price of $117.06 and a 200-day moving average price of $118.46. The company has a market capitalization of $9.08 billion, a P/E ratio of -21.33 and a beta of 0.84.

Institutional Trading of Abivax

Institutional investors have recently modified their holdings of the business. Sei Investments Co. purchased a new stake in shares of Abivax during the 3rd quarter valued at approximately $5,660,000. UBS Group AG lifted its stake in shares of Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock valued at $378,761,000 after buying an additional 4,293,606 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Abivax in the 3rd quarter worth approximately $3,557,000. Crossmark Global Holdings Inc. purchased a new stake in Abivax in the 3rd quarter worth approximately $320,000. Finally, Octagon Capital Advisors LP lifted its stake in Abivax by 3.0% in the 2nd quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock worth $9,693,000 after purchasing an additional 37,000 shares in the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABVX has been the subject of a number of research reports. Oddo Bhf reissued an “outperform” rating on shares of Abivax in a research report on Thursday, April 9th. Jefferies Financial Group assumed coverage on shares of Abivax in a research report on Monday, March 16th. They set a “buy” rating and a $160.00 target price for the company. Barclays upped their price target on shares of Abivax from $142.00 to $148.00 and gave the company an “overweight” rating in a research note on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Monday, April 20th. Finally, Wedbush assumed coverage on shares of Abivax in a research note on Tuesday, February 24th. They set an “outperform” rating and a $110.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.15.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.